Prelude Capital Management’s Pacira BioSciences PCRX Stock Holding History

Prelude Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,000	Closed	-$75K	–	1618
2017 Q3	$75K	Buy	+2,000	New	+$80.5K	0.01%	973
2017 Q2	–	Sell	-2,500	Closed	-$114K	–	1787
2017 Q1	$114K	Buy	+2,500	New	+$108K	0.01%	748
2016 Q4	–	Sell	-23,200	Closed	-$794K	–	1726
2016 Q3	$794K	Buy	+23,200	New	+$909K	0.08%	243

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's PCRX Position: Q2 2026 in Review

Prelude Capital Management reduced its Pacira BioSciences (PCRX) stake by 0.2% in Q2 2026, selling an estimated $2.36K and leaving 50,635 shares worth $1.28M. The position accounts for 0.09% of the portfolio, ranked #246.

Prelude Capital Management first reported a position in PCRX in Q2 2014 and has held it in 27 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Prelude Capital Management held 50,635 shares of Pacira BioSciences worth $1.28M as of Q2 2026.
Prelude Capital Management sold 100 Pacira BioSciences shares in Q2 2026, an estimated $2.36K.
Pacira BioSciences made up 0.09% of Prelude Capital Management's portfolio in Q2 2026, its #246 holding.
Prelude Capital Management first reported a position in Pacira BioSciences in Q2 2014 and has held it in 27 quarters since.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.